Updated Feb 25, 2007 at 15:15 EST.
The 30th volume of
Trends in Neurosciences published in February 2007, F. Giuliano discusses the role of serotonin (5-hydroxytryptamine or 5-HT) in ejaculatory control. Specifically, premature ejaculation ( PE ) may be the most closely related ejaculatory disorder that responds to selective serotonin reuptake inhibitors (SSRIs).
The most current pharmacological treatment of choice for premature ejaculation ( PE ) is through chronic dosing of SSRIs. This methodology may be changing with newer, on-demand medications like dapoxetine
( Priligy ™ ) being tested to treat premature ejaculation ( PE ). Research demonstrates that 5-HT(1B) and 5-HT(2C) receptors, when activated, delay ejaculation. On the other hand, when the 5-HT(1A) receptors are activated, ejaculation is imminent. With medications like dapoxetine
( Priligy ™ ) being developed specifically to work with receptors 5-HT(1B) and 5-HT(2C), newer therapeutic options can be explored.
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
